



Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

November 5, 2018

SEATTLE--(BUSINESS WIRE)--Nov. 5, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor conferences in November.

The company will present at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 at 2:45 pm Eastern Time in New York.

Additionally, Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine, will participate in an analyst-led fireside chat at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 1:30 pm Eastern Time in New York.

A live webcast of each presentation will be available online in the investor relations section of the company's website at <https://ir.alpineimmunesciences.com/events>. A replay of the presentations will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is the first company employing directed evolution to create potentially powerful multifunctional immunotherapies to improve patients' lives. Supported by promising preclinical data, we aim to have two programs in the clinic in 2019. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reverse pathogenic immune responses. The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 T cell costimulator intended to combine checkpoint inhibition with a necessary costimulation signal – an approach currently absent from approved checkpoint therapies. Alpine is backed by world-class research capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181105005268/en/>

Source: Alpine Immune Sciences, Inc.

Investor Relations:

Pure Communications

Courtney Dugan, 212-257-6723

cdugan@purecommunications.com

or

Media Relations:

Pure Communications

Jennifer Paganelli, 347-658-8290

jpaganelli@purecommunications.com